SCM
BCRX icon

Silverarc Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Silverarc Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-248,728
Closed -$1.49M – 82
2023
Q4 		$1.49M Sell
248,728
-542,943
-69% -$3.15M 0.44% 54
2023
Q3 		$5.61M Buy
791,671
+30,767
+4% +$221K 1.7% 23
2023
Q2 		$5.36M Buy
760,904
+183,147
+32% +$1.47M 1.66% 20
2023
Q1 		$4.82M Buy
577,757
+305,584
+112% +$2.94M 1.99% 20
2022
Q4 		$3.12M Buy
272,173
+85,570
+46% +$1.07M 0.89% 40
2022
Q3 		$2.35M Buy
186,603
+133,082
+249% +$1.71M 0.8% 40
2022
Q2 		$566K Sell
53,521
-48,904
-48% -$504K 0.17% 62
2022
Q1 		$197K Buy
+102,425
New +$1.64M 0.08% 63
2021
Q1 		– Sell
-110,000
Closed -$820K – 93
2020
Q4 		$820K Buy
+110,000
New +$567K 0.48% 54

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Silverarc Capital Management's BCRX Position: Q1 2024 in Review

Silverarc Capital Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2024, closing a stake of 248,728 shares — an estimated $1.49M sold.

Silverarc Capital Management first reported a position in BCRX in Q4 2020 and held it in 9 quarters. The position peaked at $5.61M in Q3 2023. 238 funds tracked by Wall St. Rank hold BCRX as of Q1 2024.

  • Silverarc Capital Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Silverarc Capital Management sold 248,728 BioCryst Pharmaceuticals shares in Q1 2024, an estimated $1.49M.
  • Silverarc Capital Management first reported a position in BioCryst Pharmaceuticals in Q4 2020 and held it in 9 quarters.
  • Silverarc Capital Management's BioCryst Pharmaceuticals position peaked at $5.61M in Q3 2023.
  • 238 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2024.

Based on Silverarc Capital Management's 13F filing for Q1 2024, filed 15 May 2024.